Protocol Ledger

NCT05426733 · Phase III · ACTIVE NOT RECRUITING

An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia

Interventional Phase III clinical trial protocol NCT05426733 sponsored by Albireo, an Ipsen Company in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-07-05 Enrollment: 180 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05426733
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)180 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05426733
Protocol FieldVerified Registry Value
NCT IdentifierNCT05426733
Consolidated Lead SponsorAlbireo, an Ipsen Company
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment180 participants (ESTIMATED)
Registered Start Date2022-07-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI